Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ixovex
London, United Kingdomixogen.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Ixovex-1, the lead candidate, demonstrates tumor-selective replication and efficacy in multiple preclinical models, including head and neck, NSCLC, and other solid tumors; it shows promising safety and tolerability with two mice cured in lung carcinoma models, and is ready for human clinical trials[4][7].
- Therapeutic areas
- Oncology
- Modalities
- Oncolytic virus therapyGene therapyBiologic
- Industry
- Biotech
02
Partnerships
Lonza (strategic agreement for cGMP clinical manufacturing of Ixovex-1)[2][3][4]
Beyond the preview
Go deeper on Ixovex.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ixovex.